参考文献/References:
[1] Nakagawa Y,Nishikimi T,Kuwahara K. Atrial and brain natriuretic peptides:hormones secreted from the heart[J]. Peptides,2019,111:18-25.
[2] Kuwahara K. The natriuretic peptide system in heart failure:diagnostic and therapeutic implications[J]. Pharmacol Ther,2021,227:107863.
[3] Vinnakota S,Chen HH. The importance of natriuretic peptides in cardiometabolic diseases[J]. J Endocr Soc,2020,4(6):bvaa052.
[4] Goetze JP,Bruneau BG,Ramos HR,et al. Cardiac natriuretic peptides[J]. Nat Rev Cardiol,2020,17(11):698-717.
[5] Zhao J,Xu T,Zhou Y,et al. B-type natriuretic peptide and its role in altering Ca2+-regulatory proteins in heart failure-mechanistic insights[J]. Heart Fail Rev,2020,25(5):861-871.
[6] Mani I,Garg R,Tripathi S,et al. Subcellular trafficking of guanylyl cyclase/natriuretic peptide receptor-A with concurrent generation of intracellular cGMP[J]. Biosci Rep,2015,35(5):e00260.
[7] Somanna NK,Mani I,Tripathi S,et al. Clathrin-dependent internalization,signaling,and metabolic processing of guanylyl cyclase/natriuretic peptide receptor-A[J]. Mol Cell Biochem,2018,441(1-2):135-150.
[8] Mani I,Pandey KN. Emerging concepts of receptor endocytosis and concurrent intracellular signaling:mechanisms of guanylyl cyclase/natriuretic peptide receptor-A activation and trafficking[J]. Cell Signal,2019,60:17-30.
[9] Pandey KN. Functional roles of short sequence motifs in the endocytosis of membrane receptors[J]. Front Biosci(Landmark Ed),2009,14(14):5339-5360.
[10] Coué M,Badin PM,Vila IK,et al. Defective natriuretic peptide receptor signaling in skeletal muscle links obesity to type 2 diabetes[J]. Diabetes,2015,64(12):4033-4045.
[11] Ichiki T,Jinno A,Tsuji Y. Natriuretic peptide-based novel therapeutics:long journeys of drug developments optimized for disease states[J]. Biology(Basel),2022,11(6):859.
[12] Volpe M,Battistoni A,Rubattu S. Natriuretic peptides in heart failure:current achievements and future perspectives[J]. Int J Cardiol,2019,281:186-189.
[13] Kuhn M. Molecular physiology of membrane guanylyl cyclase receptors[J]. Physiol Rev,2016,96(2):751-804.
[14] Nishikimi T,Maeda N,Matsuoka H. The role of natriuretic peptides in cardioprotection[J]. Cardiovasc Res,2006,69(2):318-328.
[15] Ponikowski P,Voors AA,Anker SD,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA) of the ESC[J]. Eur Heart J,2016,37(27):2129-2200.
[16] Yancy CW,Jessup M,Bozkurt B,et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. Circulation,2017,136(6):e137-e161.
[17] Clerico A,Recchia FA,Passino C,et al. Cardiac endocrine function is an essential component of the homeostatic regulation network:physiological and clinical implications[J]. Am J Physiol Heart Circ Physiol,2006,290(1):H17-H29.
[18] Pan HY,Zhu JH,Gu Y,et al. Comparative effects of recombinant human brain natriuretic peptide and dobutamine on acute decompensated heart failure patients with different blood BNP levels[J]. BMC Cardiovasc Disord,2014,14:31.
[19] Díez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system:implications for therapy[J]. Eur J Heart Fail,2017,19(2):167-176.
[20] 刘秀叶,崔炜,谢瑞芹,等. 基础血浆B型利钠肽水平对心力衰竭患者应用重组人B型利钠肽短期临床疗效的预测价值[J]. 中国心血管杂志,2017,22(4):243-247.
[21] 吴文佳,陆宁. rhBNP治疗急性心力衰竭的临床安全性和有效性及影响疗效的因素分析[J]. 转化医学杂志,2022,11(1):31-35.
[22] Vasile VC,Jaffe AS. Natriuretic peptides and analytical barriers[J]. Clin Chem,2017,63(1):50-58.
[23] Matsuo A,Nagai-Okatani C,Nishigori M,et al. Natriuretic peptides in human heart:novel insight into their molecular forms,functions,and diagnostic use[J]. Peptides,2019,111:3-17.
[24] D’Alessandro R,Masarone D,Buono A,et al. Natriuretic peptides:molecular biology,pathophysiology and clinical implications for the cardiologist[J]. Future Cardiol,2013,9(4):519-534.
[25] Huntley BK,Sandberg SM,Heublein DM,et al. Pro-B-type natriuretic peptide-1-108 processing and degradation in human heart failure[J]. Circ Heart Fail,2015,8(1):89-97.
[26] Nakagawa Y,Nishikimi T,Kuwahara K,et al. MiR30-GALNT1/2 axis-mediated glycosylation contributes to the increased secretion of inactive human prohormone for brain natriuretic peptide(proBNP) from failing hearts[J]. J Am Heart Assoc,2017,6(2):e003601.
[27] Kuhn M,Voss M,Mitko D,et al. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure[J]. Cardiovasc Res,2004,64(2):308-314.
[28] Knecht M,Pagel I,Langenickel T,et al. Increased expression of renal neutral endopeptidase in severe heart failure[J]. Life Sci,2002,71(23):2701-2712.
[29] Fielitz J,Dendorfer A,Pregla R,et al. Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure[J]. Circulation,2002,105(3):286-289.
[30] von Lueder TG,Sangaralingham SJ,Wang BH,et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation:novel therapeutic concepts to combat heart failure[J]. Circ Heart Fail,2013,6(3):594-605.
[31] Forfia PR,Lee M,Tunin RS,et al. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart[J]. J Am Coll Cardiol,2007,49(10):1079-1088.
[32] Singh G,Kuc RE,Maguire JJ,et al. Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart:downregulation of natriuretic peptide receptor-A in heart failure[J]. Circ Res,2006,99(2):183-190.
[33] Potter LR,Abbey-Hosch S,Dickey DM. Natriuretic peptides,their receptors,and cyclic guanosine monophosphate-dependent signaling functions[J]. Endocr Rev,2006,27(1):47-72.
[34] Yoder AR,Robinson JW,Dickey DM,et al. A functional screen provides evidence for a conserved,regulatory,juxtamembrane phosphorylation site in guanylyl cyclase a and B[J]. PLoS One,2012,7(5):e36747.
[35] Bryan PM,Xu X,Dickey DM,et al. Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations[J]. Am J Physiol Renal Physiol,2007,292(5):F1636-F1644.
[36] Gwathmey TM,Westwood BM,Pirro NT,et al. Nuclear angiotensin-(1-7) receptor is functionally coupled to the formation of nitric oxide[J]. Am J Physiol Renal Physiol,2010,299(5):F983-F990.
[37] Luo J,Zhang X,Dai Z,et al. Effect of recombinant human brain natriuretic peptide on urine volume,cardiac function and inflammatory markers in patients with acute heart failure[J]. Minerva Surg,2022 Feb 11. DOI: 10.23736/S2724-5691.21.09426-0. Epub ahead of print.
[38] de Leon H,Garcia R. Regulation of glomerular atrial natriuretic factor receptor subtypes by renal sympathetic nerves[J]. Am J Physiol,1991,260(6 Pt 2):R1043-R1050.
[39] Fu S,Ping P,Wang F,et al. Synthesis,secretion,function,metabolism and application of natriuretic peptides in heart failure[J]. J Biol Eng,2018,12:2.
[40] Yancy CW,Jessup M,Bozkurt B,et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure:an update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Task?Force?on?Clinical Practice Guidelines and the Heart Failure Society of America[J]. J Am Coll Cardiol,2016,68(13):1476-1488.
[41] Januzzi JL,Butler J,Fombu E,et al. Rationale and methods of the Prospective Study of Biomarkers,Symptom Improvement,and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure(PROVE-HF)[J]. Am Heart J,2018,199:130-136.
[42] Senni M,McMurray J,Wachter R,et al. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction:insights from the TITRATION study[J]. Eur J Heart Fail,2018,20(3):491-500.
[43] Khariton Y,Fonarow GC,Arnold SV,et al. Association between sacubitril/valsartan initiation and health status outcomes inheartfailure with reduced ejectionfraction[J]. JACC Heart Fail,2019,7(11):933-941.
[44] Myhre PL,Vaduganathan M,Claggett B,et al. B-type natriuretic peptide during treatment with sacubitril/valsartan:the?PARADIGM-HFtrial[J]. J Am Coll Cardiol,2019,73(11):1264-1272.
[45] Maddox TM,Januzzi JL Jr,Allen LA,et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment:answers to 10 pivotal issues about heart failure with reduced ejection fraction:a report of the American College of Cardiology Solution Set Oversight Committee[J]. J Am Coll Cardiol,2021,77(6):772-810.
相似文献/References:
[1]戴玫,付珞,胡建英,等.慢性心力衰竭患者应用高强度间歇性有氧训练研究进展[J].心血管病学进展,2016,(3):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
DAI Mei,FU Luo,HU Jianying,et al.Advances in Research on High-intensity Interval Training in Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2016,(3):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
[2]张培,综述,刘剑,等.慢性心力衰竭并发肌少症的研究进展[J].心血管病学进展,2016,(3):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
ZHANG Pei,LIU Jian.Research Progress in Chronic Heart Failure-induced Sarcopenia[J].Advances in Cardiovascular Diseases,2016,(3):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
[3]田晶,张青,张岩波,等.慢性心力衰竭结局评价指标研究进展[J].心血管病学进展,2019,(6):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
TIAN Jing,ZHANG qing,ZHANG Yanbo,et al.Outcome Indicators for Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2019,(3):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
[4]胡威,苏芳菊,张卫泽.左室四极导线在心脏再同步化治疗中的应用进展[J].心血管病学进展,2020,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
HU Wei,SU Fangju,ZHANG Weize.Application of Left Ventricular Quadrupole in Cardiac Resynchronization Therapy[J].Advances in Cardiovascular Diseases,2020,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
[5]郭岐龙 芦颜美 张玲 张疆华 邢强 祖克拉·吐尔洪 李耀东 周贤惠 汤宝鹏.新疆地区老年慢性心力衰竭住院患者的病因、合并症及药物治疗的多中心回顾性分析[J].心血管病学进展,2020,(4):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
GUO Qilong,LU Yanmei,ZHANG Ling,et al.Etiology, Comorbidity and Drug Treatment of Elderly Inpatients with Chronic Heart Failure in Xinjiang: A Multi-center Retrospective Study[J].Advances in Cardiovascular Diseases,2020,(3):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
[6]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(3):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[7]郭曦滢,孙煌,樊朝美,等.非奈利酮治疗慢性心力衰竭的研究进展[J].心血管病学进展,2020,(10):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
GUO XiyingSUN HuangFAN ChaomeiZHANG Jian.Finerenone in the Treatment of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(3):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
[8]吴燕婷 李萍 吴寒.慢性心力衰竭再住院率研究进展[J].心血管病学进展,2021,(8):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
WU Yanting,LI Ping,WU Han.Rehospitalization Rate of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2021,(3):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
[9]陈晓梅 陈巧玮 曾纪娟 张庆.可穿戴设备在慢性心力衰竭患者管理中的应用进展[J].心血管病学进展,2023,(3):233.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.010]
CHEN Xiaomei,CHEN Qiaowei,ZENG Jijuan,et al.Application of Wearable Devices in Management of Patients with Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2023,(3):233.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.010]
[10]高亮 芦颜美.慢性心力衰竭并发肌少症和恶病质的诊治进展[J].心血管病学进展,2023,(7):598.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.006]
GAO Liang,LU Yanmei.Diagnosis and Treatment of Chronic Heart Failure Complicated with Sarcopenia and Cachexia[J].Advances in Cardiovascular Diseases,2023,(3):598.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.006]